Novo Nordisk already has an oral version of semaglutide, the active ingredient in Ozempic and Wegovy, on the market in Rybelsus, which was first approved in 2019, but that is indicated for treating Type 2 diabetes, not obesity
412 min 100% B
Clinical trials report meaningful average weight loss, with results varying by product, dose, trial design, and adherence
Biomedicine, 1997
It is not a substitute for calorie control, exercise, and sleep but can be a helpful adjunct when combined with sensible lifestyle changes
File usage on other wikis The following other wikis use this file: Usage on en.wikipedia.org User:Mm9656/sandbox Usage on zh.wikipedia.org Metadata This file contains additional information such as Exif metadata which may have been added by the digital camera, scanner, or software program used to create or digitize it